Vanderbilt Health Leads Multi-National SOPHIA2 Clinical Trial Evaluating UroActive Artificial Sphincter for Male Stress Urinary Incontinence

Vanderbilt Health leads the SOPHIA2 trial to evaluate the UroActive implant, an activity-controlled solution for men suffering from stress urinary incontinence.

By: AXL Media

Published: Mar 13, 2026, 5:38 AM EDT

Source: Information for this report was sourced from Vanderbilt University Medical Center

Addressing a Debilitating Global Quality-of-Life Crisis

Stress urinary incontinence (SUI), defined as involuntary urinary leakage during physical activity or coughing, remains a profound healthcare challenge affecting approximately 40 million Americans and 90 million Europeans. Beyond the physical symptoms, the condition is often debilitating, frequently resulting in social stigma, low self-esteem, and clinical depression. Current treatment options have historically faced limitations in user experience and long-term efficacy. Dr. Melissa Kaufman, chief of Reconstructive Urology and Pelvic Health at Vanderbilt Health, notes that the SOPHIA2 trial is a direct response to the shortcomings of existing therapies, offering a potential breakthrough for patients who have struggled with the limitations of traditional surgical interventions.

The Mechanics of Activity-Controlled Urethral Support

The UroActive implant represents a significant technological shift in how SUI is managed surgically. Unlike traditional artificial urinary sphincters that may require complex manual manipulation to operate, this new device is placed around the urethral duct and is designed to be controlled based on the patient's specific activity level. This automation is intended to provide ease of use and a more seamless integration into daily life. By providing a responsive mechanism that adjusts to physical demands, the implant aims to restore continence more naturally, significantly improving the overall impression of health and independence for the user.

Clinical Feasibility and First-in-Human Success

The move toward the larger SOPHIA2 trial follows encouraging data from the initial first-in-human SOPHIA study presented at the American Urological Association 2024 Annual Meeting. In that preliminary group, the UroActive device was successfully implanted and activated in all six participants without the need for surgical revisions or device explants. While one patient experienced a postoperative hematoma that resolved on its own, the overall outcomes met all primary and secondary safety and efficacy endpoints. These results have provided the necessary foundation for the U.S. Food and Drug Administration (FDA) and French regulatory agencies to clear the current expanded multi-national investigation.